

S3 Table. Relationships between MPV, PDW/PCT and clinicopathological characteristics

Levels	PDW/PCT		p-value	MPV (fl)		p-value
	≤190	>190		≤8.1	>8.1	
No.	232	276		166	349	
Type						
GBC	39 (16.8)	78 (28.3)	0.001*	53 (31.9)	69 (19.8)	0.001*
ECC	151 (65.1)	137 (49.6)		75 (45.2)	215 (61.6)	
ICC	42 (18.1)	61 (22.1)		38 (22.9)	65 (18.6)	
Age (yr)						
≤ 60	107 (46.1)	118 (42.8)	0.502	76 (45.8)	152 (43.6)	0.703
> 60	125 (53.9)	158 (57.2)		90 (54.2)	197 (56.4)	
Sex						
Female	112 (48.3)	115 (41.7)	0.161	79 (47.6)	152 (43.6)	0.444
Male	120 (51.7)	161 (58.3)		87 (52.4)	197 (56.4)	
Blood type						
AB	18 (7.8)	15 (5.5)	0.576	5 (3.0)	28 (8.0)	0.130
A	46 (19.9)	65 (23.6)		40 (24.2)	73 (21.0)	
B	97 (42.0)	110 (40.0)		65 (39.4)	145 (41.7)	
O	70 (30.3)	85 (30.9)		55 (33.3)	102 (29.3)	
Fever						
No	193 (83.2)	242 (87.7)	0.190	138 (83.1)	304 (87.1)	0.283
Yes	39 (16.8)	34 (12.3)		28 (16.9)	45 (12.9)	
Emaciation						
No	89 (38.9)	158 (57.7)	<0.001*	92 (55.4)	161 (46.8)	0.084
Yes	140 (61.1)	116 (42.3)		74 (44.6)	183 (53.2)	
Debilitation						
No	204 (88.3)	245 (89.1)	0.893	146 (88.5)	309 (88.8)	>0.99
Yes	27 (11.7)	30 (10.9)		19 (11.5)	39 (11.2)	
Drink						
No	184 (79.7)	204 (74.2)	0.179	128 (77.6)	265 (76.1)	0.807
Yes	47 (20.3)	71 (25.8)		37 (22.4)	83 (23.9)	
Fat liver						
No	202 (90.6)	234 (93.2)	0.374	147 (93.0)	294 (91.0)	0.564
Yes	21 (9.4)	17 (6.8)		11 (7.0)	29 (9.0)	
ALT (U/L)						
≤ 100	114 (49.1)	169 (61.2)	0.008*	110 (66.3)	179 (51.4)	0.002*
> 100	118 (50.9)	107 (38.8)		56 (33.7)	169 (48.6)	
AST (U/L)						
≤ 100	131 (61.5)	204 (75.0)	0.002*	130 (79.8)	211 (64.3)	0.001*
> 100	82 (38.5)	68 (25.0)		33 (20.2)	117 (35.7)	
GGT (U/L)						
≤ 200	84 (39.1)	138 (50.9)	0.012*	97 (59.9)	129 (39.1)	<0.001*

> 200	131 (60.9)	133 (49.1)		65 (40.1)	201 (60.9)	
ALP (U/L)						
≤ 200	73 (34.0)	146 (53.9)	< 0.001*	97 (59.9)	127 (38.5)	<0.001*
> 200	142 (66.0)	125 (46.1)		65 (40.1)	203 (61.5)	
ALB (g/L)			0.004*			0.004*
≤ 35	64 (27.7)	46 (16.7)		23 (13.9)	88 (25.4)	
> 35	167 (72.3)	229 (83.3)		143 (86.1)	259 (74.6)	
TBIL (μmol/L)			<0.001*			<0.001*
≤ 106	116 (50.0)	194 (70.3)		127 (76.5)	188 (53.9)	
> 106	116 (50.0)	82 (29.7)		39 (23.5)	161 (46.1)	
CA19-9 (U/mL)			<0.001*			<0.001*
≤ 100	88 (40.4)	160 (59.9)		102 (63.4)	150 (45.5)	
> 100	130 (59.6)	107 (40.1)		59 (36.6)	180 (54.5)	
Tumor differentiation						
Poor	23 (10.2)	25 (9.6)	0.826	16 (10.0)	34 (10.2)	0.214
Moderate	121 (53.8)	135 (51.7)		75 (46.9)	182 (54.7)	
Well	81 (36.0)	101 (38.7)		69 (43.1)	117 (35.1)	
Radical cure						
No	100 (43.5)	95 (34.8)	0.058	63 (38.2)	133 (38.6)	1.000
Yes	130 (56.5)	178 (65.2)		102 (61.8)	212 (61.4)	
T stage						
Tis	1 (0.4)	8 (2.9)	0.059	4 (2.4)	5 (1.4)	0.261
1	49 (21.1)	74 (26.8)		47 (28.3)	78 (22.3)	
2	77 (33.2)	72 (26.1)		41 (24.7)	109 (31.2)	
3	90 (38.8)	99 (35.9)		59 (35.5)	134 (38.4)	
4	15 (6.5)	23 (8.3)		15 (9.0)	23 (6.6)	
Nodal involvement						
No	153 (65.9)	196 (71.3)	0.233	127 (76.5)	228 (65.5)	0.016*
Yes	79 (34.1)	79 (28.7)		39 (23.5)	120 (34.5)	
TNM stage						
0	1 (0.4)	8 (2.9)	0.039*	5 (3.0)	4 (1.1)	0.072
I	78 (33.6)	95 (34.4)		58 (34.9)	116 (33.2)	
II	88 (37.9)	81 (29.3)		44 (26.5)	126 (36.1)	
III	65 (28.0)	92 (33.3)		59 (35.5)	103 (29.5)	
Tumor size (cm)						
≤ 2.6	140 (63.9)	151 (57.0)	0.144	85 (53.1)	211 (63.7)	0.031*
> 2.6	79 (36.1)	114 (43.0)		75 (46.9)	120 (36.3)	

Values are presented as number (%). ALB, albumin; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CA19-9, carbohydrate antigen 19-9; ECC, extrahepatic cholangiocarcinoma; GBC, gallbladder cancer; GGT, γ -glutamyl transpeptidase; ICC, intrahepatic cholangiocarcinoma; PCT, plateletcrit; PDW, platelet

distribution width; MPV, mean platelet volume; TBIL, total bilirubin. *Statistically significant ($p < 0.05$).